RUNX1 and acute myeloid leukemia: At present, in the study of acute myeloid leukemia, it has been shown that the survival rate of AML mouse models with mtRUNX1 expression can be effectively improved by CRISPR/Cas9 editing technology and the application of RUNX1 inhibitors38,39.